1. Semaglutide reduced HbA1c by nearly 0.5%.
2. Average weight loss was 20 pounds over 30 weeks.
3. 81% of patients on semaglutide achieved HbA1c levels below prediabetes threshold.
4. No worsening in psychiatric symptoms was reported.
5. Trial duration was 30 weeks and conducted in Denmark.
6. Only stable treatment patients were included, diabetes patients were excluded.
7. Gastrointestinal adverse events were noted but serious adverse events were similar across groups.

Source: JAMA Psychiatry